SMTL ID : 8stg.1 (1 other biounit)

Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.79 Å

Oligo State

monomer

Ligands

1 x WCJ: N-{4-[(5P)-4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-2-methylpropanamide(Non-covalent)

WCJ.1: 26 residues within 4Å: Chain A: L.35, G.36, E.37, G.38, C.39, F.40, V.43, A.63, K.65, E.82, M.85, M.86, I.96, V.112, E.113, Y.114, A.115, N.119, R.178, N.179, L.181, I.190, A.191, D.192, F.193, G.194 13 PLIP interactions: 13 interactions with chain A Hydrophobic interactions: A:F.40, A:V.43, A:V.43, A:K.65, A:V.112, A:L.181, A:A.191 Hydrogen bonds: A:E.82, A:E.113, A:A.115, A:N.179, A:D.192 pi-Stacking: A:F.193

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Subbiah, V. et al., RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov (2023)

Release Date

2023-06-07

Peptides

Fibroblast growth factor receptor 2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Fibroblast growth factor receptor 2

Related Entries With Identical Sequence